Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment
Junshi Biosciences (HKG: 1877; SHA: 688180), a leading biopharmaceutical company in China, has announced that...
WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development...
Juventas Cell Therapy’s CAR-T Therapy Clears for SLE-ITP Study in China
The China Center for Drug Evaluation (CDE) has given the green light for a study...
Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the...
SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) has unveiled the “Guidelines for Compliance of Pharmaceutical...
JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services
JD Healthcare, a subsidiary of China’s e-commerce juggernaut JD.com (NASDAQ: JD), has formed a strategic...
Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
The People’s Government of Guangdong Province has unveiled an ambitious “Action Plan for Further Promoting...
Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...
Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked...
Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B
Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...
Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries
Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...
Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors
Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform
Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...
XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery
XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...
Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology
Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...
Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard
Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...
Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...